Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning

Xiangyu Li,Woonghee Kim,Kajetan Juszczak,Muhammad Arif,Yusuke Sato,Haruki Kume,Seishi Ogawa,Hasan Turkez,Jan Boren,Jens Nielsen,Mathias Uhlen,Cheng Zhang,Adil Mardinoglu
DOI: https://doi.org/10.1016/j.isci.2021.102722
IF: 5.8
2021-07-01
iScience
Abstract:Clear cell renal cell carcinoma (ccRCC) is the most common histological type of kidney cancer and has high heterogeneity. Stratification of ccRCC is important since distinct subtypes differ in prognosis and treatment. Here, we applied a systems biology approach to stratify ccRCC into three molecular subtypes with different mRNA expression patterns and prognosis of patients. Further, we developed a set of biomarkers that could robustly classify the patients into each of the three subtypes and predict the prognosis of patients. Then, we reconstructed subtype-specific metabolic models and performed essential gene analysis to identify the potential drug targets. We identified four drug targets, including <i>SOAT1</i>, <i>CRLS1, and ACACB,</i> essential in all the three subtypes and <i>GPD2</i>, exclusively essential to subtype 1. Finally, we repositioned mitotane, an FDA-approved <i>SOAT1</i> inhibitor, to treat ccRCC and showed that it decreased tumor cell viability and inhibited tumor cell growth based on <i>in vitro</i> experiments.
multidisciplinary sciences
What problem does this paper attempt to address?